Uni Eropa - Slovak - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - antiparazitárne prípravky, insekticídy a repelenty - dogs; cats; ferrets - dogsfor psov, ktorí trpia, alebo na riziko, zmiešané parazitárnych infekcií:liečba a prevencia velká napadnutia (ctenocephalides felis),liečbu hryzenie vší (trichodectes canis),ošetrenie uší roztoč napadnutia (otodectes cynotis), sarcoptic mange (spôsobené sarcoptes scabiei var. canis), demodicosis (spôsobené demodex canis),prevenciu heartworm ochorenia (l3 a l4 lariev z dirofilaria immitis),na liečbu obehového microfilariae (dirofilaria immitis),pri liečbe kožných dirofilariosis (pre dospelých štádií dirofilaria serenoa), na prevenciu kožných dirofilariosis (larvy l3 z dirofilaria serenoa),zníženie obehu microfilariae (dirofilaria serenoa),prevenciu angiostrongylosis (larvy l4 a nezrelé dospelých angiostrongylus vasorum),liečbu angiostrongylus vasorum a crenosoma vulpis,prevencia spirocercosis (spirocerca lupi),liečbu eucoleus (syn. capillaria) boehmi (dospelí),ošetrenie očí červ thelazia callipaeda (dospelí),na liečbu infekcie s gastrointestinálnymi háďatká (larvy l4, nezrelé dospelých a dospelých toxocara canis, ancylostoma caninum a uncinaria stenocephala, dospelí toxascaris leonina a trichuris vulpis). výrobok sa môže používať ako súčasť stratégie liečby pre velká alergie dermatitída (fad). catsfor mačky trpiace, alebo na riziko, zmiešané parazitárnych infekcií:liečba a prevencia velká napadnutia (ctenocephalides felis),ošetrenie uší roztoč napadnutia (otodectes cynotis),liečbu notoedric mange (notoedres cati),spracovanie lungworm eucoleus aerophilus (syn. capillaria aerophila) (dospelí),prevenciu lungworm ochorenia (l3/l4 lariev z aelurostrongylus abstrusus),spracovanie lungworm aelurostrongylus abstrusus (dospelí),čistenie očí červ thelazia callipaeda (dospelí),prevenciu heartworm ochorenia (l3 a l4 lariev z dirofilaria immitis),pri liečbe infekcií s gastrointestinálnymi háďatká (larvy l4, nezrelé dospelých a dospelých toxocara cati a ancylostoma tubaeforme). výrobok sa môže používať ako súčasť stratégie liečby pre velká alergie dermatitída (fad). ferretsfor fretky, ktorí trpia, alebo na riziko, zmiešané parazitárnych infekcií:liečba a prevencia velká napadnutia (ctenocephalides felis),prevenciu heartworm ochorenia (l3 a l4 lariev z dirofilaria immitis).

Uni Eropa - Slovak - EMA (European Medicines Agency)

eisai gmbh - lenvatinib mesilát - karcinóm, obličková bunka - antineoplastické činidlá - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.

Uni Eropa - Slovak - EMA (European Medicines Agency)

teva b.v. - lipegfilgrastim - neutropénia - immunostimulants, , kolónie stimulujúci faktory - lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Uni Eropa - Slovak - EMA (European Medicines Agency)

roche registration gmbh - methoxy polyetylénglykolu-epoetin beta - anemia; kidney failure, chronic - antianemické prípravky - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.

Uni Eropa - Slovak - EMA (European Medicines Agency)

teva pharma b.v. - pioglitazón hydrochlorid - diabetes mellitus, typ 2 - lieky používané pri cukrovke - pioglitazone is indicated in the treatment of type-2 diabetes mellitus as monotherapy: , in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. , pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance. po začatí liečby s pioglitazone, pacienti by mali byť preskúmané po 3 až 6 mesiacov na posúdenie primeranosti odpoveď na liečbu (e. zníženie hba1c). u pacientov, ktorí nedokážu zobraziť primeranú odpoveď, pioglitazone by mali byť ukončené. z hľadiska potenciálnych rizík s dlhodobou liečbou, prescribers by mal potvrdiť na následné bežné recenzie, ktoré v prospech pioglitazone je zachovaná.

Uni Eropa - Slovak - EMA (European Medicines Agency)

merck sharp & dohme b.v. - tedizolid fosfát - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.

Uni Eropa - Slovak - EMA (European Medicines Agency)

astrazeneca ab - osimertinib mesilate - karcinóm, pľúc bez malých buniek - iné antineoplastické činidlá, protein kinase inhibítory - tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations- the first-line treatment of adult patients nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc. tagrisso as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage ib-iiia non-small cell lung cancer (nsclc) whose tumours have epidermal growth factor receptor (egfr) exon 19 deletions or exon 21 (l858r) substitution mutations. - the first-line treatment of adult patients with locally advanced or metastatic nsclc with activating egfr mutations. - the treatment of adult patients with locally advanced or metastatic egfr t790m mutation-positive nsclc.

Uni Eropa - Slovak - EMA (European Medicines Agency)

zentiva, k.s. - pregabalín - anxiety disorders; epilepsy - antiepileptiká, - neuropathic pain , pregabalin zentiva is indicated for the treatment of peripheral and central neuropathic pain in adults. , epilepsy , pregabalin zentiva is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. , generalised anxiety disorder , pregabalin zentiva is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Uni Eropa - Slovak - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - lieky na liečbu hyperkalemia a hyperphosphatemia - velphoro je indikovaná na kontrolu hladiny fosforu v sére dospelých chronickou obličkovou chorobou (ckd) pacientov na hemodialýze (hd) alebo peritoneálnej dialýze (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.

Uni Eropa - Slovak - EMA (European Medicines Agency)

sandoz gmbh - rituximab - lymphoma, non-hodgkin; arthritis, rheumatoid; microscopic polyangiitis; wegener granulomatosis - antineoplastické činidlá - riximyo is indicated in adults for the following indications:non-hodgkin’s lymphoma (nhl)riximyo is indicated for the treatment of previously untreated adult patients with stage iii-iv follicular lymphoma in combination with chemotherapy. riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy. riximyo monotherapy is indicated for treatment of adult patients with stage iii-iv follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy. riximyo is indicated for the treatment of adult patients with cd20 positive diffuse large b cell non-hodgkin’s lymphoma in combination with chop (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy. riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage cd20 positive diffuse large b-cell lymphoma (dlbcl), burkitt lymphoma (bl)/burkitt leukaemia (mature b-cell acute leukaemia) (bal) or burkitt-like lymphoma (bll). chronic lymphocytic leukaemia (cll)riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. len obmedzené údaje o účinnosti a bezpečnosti pacientov v minulosti liečených monoklonálne protilátky, vrátane rituximab alebo pacientov, žiaruvzdorné na predchádzajúcu rituximab plus chemoterapia. pozri časť 5. 1 pre ďalšie informácie. rheumatoid arthritisriximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (dmard) including one or more tumour necrosis factor (tnf) inhibitor therapies. rituximab bolo preukázané, že znižujú rýchlosť progresie poškodenia kĺbov, merané podľa x-ray a zlepšiť fyzickú funkciu, keď uvedené v kombinácii s metotrexátom. granulomatosis with polyangiitis and microscopic polyangiitisriximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (wegener’s) (gpa) and microscopic polyangiitis (mpa). riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active gpa (wegener’s) and mpa. pemphigus vulgarisriximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (pv).